Imagine a gene therapy treatment that gives drug-resistant focal epilepsy patients more control over their seizures and ultimately improve their quality of life?

We sat down with Karin Agerman to discuss this possibility and discovered that her work at Combigene is at the forefront of a novel gene therapy called CG01.

Find out how this single-injection therapy is giving renewed hope to this patient population and learn more about CombiGene’s research into CG01.

SHOW NOTES

• Cell and Gene Therapy Services and Products
• CombiGene
• Gene Therapy, A Promising Future for Epileptic Drug Development
• High Quality Plasmid DNA: A Case for Phase Dependent Approaches to Manufacturing
• Tailored Preclinical Support for Your Cell & Gene Therapies Digital Resources
• Cell and Gene Therapy Development Video Series
• Charles River Completes the Acquisition of Cognate BioServices
• CombiGene initiates GMP production of CG01 for the first-in-human study
• Navigating the ATMP Regulatory Landscape